# OnCo record idea-prostate-per-lesion-mri-audit-before-focal-treatment (idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/ideas/idea-prostate-per-lesion-mri-audit-before-focal-treatment/>
  a schema:CreativeWork ;
  onco:kind "idea" ;
  schema:identifier "idea-prostate-per-lesion-mri-audit-before-focal-treatment" ;
  schema:name "Publish a per-lesion miss rate for every prostate MRI service before it is allowed to guide focal treatment"@en ;
  schema:alternateName "per-lesion MRI audit prostate"@en, "whole-mount pathology audit focal therapy"@en, "MRI miss rate reporting"@en ;
  schema:description "Prostate MRI is good at telling you whether a man has a serious cancer and poor at telling you where all of it is. It missed at least one significant tumour in a third of men in the study that checked it against the whole removed prostate. Services that treat part of the gland, or follow men on imaging alone, are relying on the number they do not measure."@en ;
  schema:url <https://onco.cc/ideas/idea-prostate-per-lesion-mri-audit-before-focal-treatment/> ;
  schema:dateModified "2026-09-25"^^xsd:date ;
  onco:tag "prostate-evidence" ;
  onco:related <https://onco.cc/ideas/idea-fund-device-technique-registry/>, <https://onco.cc/ideas/idea-fund-ablation-versus-surgery-trials/>, <https://onco.cc/ideas/idea-prev-prostate-as-triggered-biopsy/>, <https://onco.cc/roadmaps/prostate-roadmap/> ;
  onco:cancers <https://onco.cc/cancers/prostate/>, <https://onco.cc/cancers/prostate-low-risk/>, <https://onco.cc/cancers/prostate-intermediate-risk/>, <https://onco.cc/cancers/prostate-high-risk/> ;
  onco:sections <https://onco.cc/fronts/imaging/>, <https://onco.cc/fronts/diagnostics/>, <https://onco.cc/fronts/surgery/> ;
  onco:technologies <https://onco.cc/technologies/mri/>, <https://onco.cc/technologies/active-surveillance/>, <https://onco.cc/technologies/prostate-screening-psa-mri/> ;
  onco:terms <https://onco.cc/terms/gleason-grade-group/>, <https://onco.cc/terms/prostatectomy/>, <https://onco.cc/terms/whole-mount-pathology/>, <https://onco.cc/terms/pi-rads/>, <https://onco.cc/terms/template-mapping-biopsy/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-biomarker-validation/>, <https://onco.cc/bottlenecks/b-surgery-radiation-innovation/>, <https://onco.cc/bottlenecks/b-overdiagnosis/>, <https://onco.cc/bottlenecks/b-real-world-evidence/>, <https://onco.cc/bottlenecks/b-ai-validation/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-johnson-mpmri-individual-foci-eur-urol-2019/>, <https://onco.cc/key-papers/paper-ahmed-promis-multiparametric-mri-lancet-2017/>, <https://onco.cc/key-papers/paper-precision-mri-targeted-biopsy-nejm-2018/>, <https://onco.cc/key-papers/paper-klotz-active-surveillance-jco-2015/> .